<DOC>
	<DOCNO>NCT01592136</DOCNO>
	<brief_summary>This protocol allow expand access ponatinib patient ≥18 year chronic myeloid leukemia ( CML ) phase Philadelphia chromosome positive acute lymphoblastic leukemia ( Ph+ALL ) fail available treatment option .</brief_summary>
	<brief_title>Expanded Access Program Ponatinib</brief_title>
	<detailed_description>This protocol allow expand access ponatinib patient ≥18 year CML Ph+ALL fail available treatment option . Patients chronic ( CP ) accelerate phase ( AP ) CML must previously treat resistant intolerant imatinib , dasatinib nilotinib develop T315I mutation tyrosine kinase inhibitor ( TKI ) therapy . Patients blast phase ( BP ) CML Ph+ ALL must previously treat resistant intolerant imatinib dasatinib develop T315I mutation TKI therapy . No formal analysis perform data obtain . Safety information collect adverse event tabulate reporting purpose .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>Main 1 . CPCML APCML patient previously treat resistant intolerant imatinib , dasatinib nilotinib develop T315I mutation TKI therapy . BPCML Ph+ ALL patient previously treat resistant intolerant imatinib dasatinib develop T315I mutation TKI therapy . 2 . Patients must ≥ 18 year old . 3 . Provide write informed consent . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 5 . Men woman childbearing potential must agree effective contraception time sign informed consent Followup Visit , approximately 30 day last dose ponatinib . Main Patients eligible participation study meet follow exclusion criterion : 1 . Are eligible ongoing accessible clinical trial ponatinib 2 . Have adequately recover AEs due agent previously administer 3 . Require concurrent treatment immunosuppressive agent , corticosteroid prescribe short course therapy . 4 . Have previously treat ponatinib . 5 . Have significant active cardiovascular disease , specifically include , restrict : Myocardial infarction within 3 month prior first dose ponatinib , History clinically significant atrial arrhythmia ventricular arrhythmia , Unstable angina within 3 month prior first dose ponatinib , Congestive heart failure within 3 month prior first dose ponatinib . 6 . Have abnormal QTcF ( &gt; 450 m male &gt; 470 ms female ) 7 . Have significant bleeding disorder unrelated CML Ph+ ALL . 8 . Have history pancreatitis alcohol abuse 9 . Have elevate amylase lipase ( &gt; 1.5 x ULN institution ) entry . 10 . Have inadequate hepatic function follow : Total bilirubin &gt; 1.5 x ULN institution entry Alanine aminotransferase aspartate aminotransferase &gt; 2.5 x ULN institution entry Prothrombin time &gt; 1.5 x ULN institution entry 11 . Have inadequate renal function serum creatinine &gt; 2.5 x ULN institution entry 12 . Have uncontrolled hypertriglyceridemia triglyceride &gt; 450 mg/dL entry . 13 . Have malabsorption syndrome gastrointestinal illness could affect absorption orally administer ponatinib . 14 . Women pregnant lactating . 15 . Underwent major surgery within 14 day prior first dose ponatinib . 16 . Have ongoing active infection ( include know history human immunodeficiency virus [ HIV ] , hepatitis B virus [ HBV ] , hepatitis C virus [ HCV ] ) . 17 . Suffer condition illness , opinion Investigator would compromise patient safety interfere evaluation safety study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Ponatinib</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
</DOC>